Human cells with acute myelocytic leukemia (AML) in the pericardial fluid, shown with an esterase stain at 400x.
Credit: National Cancer Institute
Acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes a large number of abnormal blood cells. It is the most common type of acute leukemia in adults and usually worsens quickly if it is not treated. Sometimes, the disease can relapse after a stem cell transplantation from a donor. A clinical trial led by Nirali N. Shah, M.D., M.H.Sc., Lasker Clinical Research Scholar in the Pediatric Oncology Branch, is studying the use of CAR T-cell therapy for patients with relapsed or refractory AML after an allogeneic hematopoietic stem cell transplant.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact the NCI Leukemia, Lymphoma, Transplant and Cell Therapy Team at ncilltct@mail.nih.gov
Clinicaltrials.gov identifier: NCT05984199
NCI Protocol ID: IRB001784
Official Title: Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
